EGFRxCD16 双特异性抗体联合溶瘤病毒驱动 NK 细胞介导的卵巢癌与 NSCLC 细胞系高效裂解

EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic virus

编码 TGF-β 抑制剂的溶瘤腺病毒与 PD-1 阻断协同增强 NK 细胞对 NSCLC 的细胞毒性

Oncolytic adenovirus encoding a TGF-β inhibitor synergizes with PD-1 blockade to potentiate NK cell cytotoxicity against NSCLC.

我们的研究结果表明，PD-1 抗体、NK 细胞与溶瘤腺病毒 Ad-anti-TGF- RII 的联合方案，通过重塑肿瘤微环境（TME）以克服 ICI 耐药，是 NSCLC 的一种有前景的治疗策略。

2025 年肺癌免疫治疗：我们身处何处，下一步是什么？

Lung cancer immunotherapy in 2025: where we stand and what comes next?

KRAS(G12C) 特异性抑制剂诱导肿瘤特异性免疫并与溶瘤病毒协同增强癌症免疫治疗

Specific inhibitor to KRAS(G12C) induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy.

KRAS G12C 小分子抑制剂是肿瘤特异性免疫的新型诱导剂，一种独特的三联组合方案通过激发强效抗肿瘤免疫，对 KRAS G12C 癌症具有高度疗效。

携带 CLEC2A 基因的溶瘤痘苗病毒增强病毒复制和抗肿瘤疗效

Oncolytic vaccinia virus harboring CLEC2A gene enhances viral replication and antitumor efficacy.

携带新型 CD137 免疫检查点刺激剂激动剂的溶瘤腺病毒抑制肿瘤生长

Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.

复制缺陷型流感 A 病毒携带 IFN-γ有效介导荷肺癌小鼠的免疫调节和肿瘤破坏

Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer

递送新型膜锚定 Fc 嵌合体增强 NK 细胞对肿瘤细胞和持续病毒感染细胞的杀伤

Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells.